The Venture Codex Logo

The Venture Codex

Med-Fine Capital

Longhua Road 858, Building B, 7th Floor Huangpu District, Shanghai, 200023, China

Overview

Venture capital firm investing in early-stage healthcare in China.

Founded

2014

Deals · 12mo

2

Links

WebsiteLinkedIn

Stage focus

Series A
Series B

Geographic focus

China
United States

Sector focus

Finance
Financial Services
Venture Capital

Investment portfolio

9rounds
NAMEDATESIZE
Excalipoint Therapeutics
Mar 2026Participated
$28 MSeed
Phrontline Biopharma
Nov 2025Participated
$60 MSeries A
Allink Biotherapeutics
Nov 2024Participated
$42 MSeries A
Rebbeca Med
Feb 2024Led
$9 MSeries A
Larkspur Biosciences
May 2023Participated
$36 MOther Equity
Degron Therapeutics
Jun 2022Led
$22 MSeries A
Allorion Therapeutics
Nov 2021Participated
$40 MSeries A
LYNK Pharmaceuticals
Aug 2021Participated
$50 MSeries B
Alebund Pharmaceuticals
May 2021Participated
$60 MSeries B
Excalipoint Therapeutics
Mar 2026Participated
$28 MSeed
Phrontline Biopharma
Nov 2025Participated
$60 MSeries A
Allink Biotherapeutics
Nov 2024Participated
$42 MSeries A
Rebbeca Med
Feb 2024Led
$9 MSeries A
Larkspur Biosciences
May 2023Participated
$36 MOther Equity
Degron Therapeutics
Jun 2022Led
$22 MSeries A
Allorion Therapeutics
Nov 2021Participated
$40 MSeries A
LYNK Pharmaceuticals
Aug 2021Participated
$50 MSeries B
Alebund Pharmaceuticals
May 2021Participated
$60 MSeries B
9
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Med-Fine Capital: 9 funding rounds are recorded in the selected participation categories.All available history.
Med-Fine Capital: 9 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed01
Series A23
Series B02
Other Equity01

Monthly Deal Activity

Med-Fine Capital: 9 deals are recorded across 66 months.All available history.
Med-Fine Capital: 9 deals are recorded across 66 months. All available history
MonthDeals
May '211
Jun '210
Jul '210
Aug '211
Sep '210
Oct '210
Nov '211
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '221
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '231
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '241
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '241
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '251
Dec '250
Jan '260
Feb '260
Mar '261
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Med-Fine Capital: Health & Life Sciences is the largest displayed sector by deal count (9 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Med-Fine Capital: Health & Life Sciences is the largest displayed sector by deal count (9 deals). All available history
SectorDeals
Health & Life Sciences9
Manufacturing1

Deal Size Distribution

Med-Fine Capital: 9 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Med-Fine Capital: 9 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M1
$10M-$25M1
$25M-$50M4
$50M-$100M3
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Med-Fine Capital: China has the largest recorded deal count among the displayed regions (6 deals).All available history.

Top 3 of 3 regions; European countries are grouped as Europe.

Med-Fine Capital: China has the largest recorded deal count among the displayed regions (6 deals). All available history
RegionDeals
China6
United States2
Hong Kong1
Med-Fine Capital: 20 co-investors are shown, with Lilly Asia Ventures sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Med-Fine Capital: 20 co-investors are shown, with Lilly Asia Ventures sharing 3 recorded deals. All available history
Co-investorShared deals
Lilly Asia Ventures3
3E Bioventures Capital2
Co-win Ventures2
Legend Capital2
5Y Capital1
Apricot Capital1
Baidu Ventures1
Centurium Capital1
Cornell University1
Creacion Ventures1
Decheng Capital1
Dyee Capital1
Eisai Innovation1
Elikon Venture1
Gaorong Capital1
HEDA Ventures1
Hony Capital1
IDG Capital1
Lapam Capital1
LS Polaris Innovation Fund1

Investment Strategy

Med-Fine Capital: Led accounts for 22% and participating for 78% of round participation.All available history.
Med-Fine Capital: Led accounts for 22% and participating for 78% of round participation. All available history
CategoryDeals (count)Share (%)
Led222%
Participating778%
Med-Fine Capital: Single-lead accounts for 100% and co-led for 0% of lead dynamics.All available history.
Med-Fine Capital: Single-lead accounts for 100% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead2100%
Co-led00%

Team

Hu Hongdan

executive director